Kura Oncology (KURA) EBIT Margin (2025 - 2026)
Kura Oncology's (KURA) quarterly EBIT Margin came in at 431.51% in Q1 2026, up 2710.0% year-on-year from 15.36% in Q1 2025, and up 7.17% on a QoQ basis from 464.82% in Q4 2025.
Kura Oncology (KURA) EBIT Margin (2025 - 2026) Analysis & Trends
Kura Oncology (KURA) has 2 years of EBIT Margin data on file, last reported at 431.51% in Q1 2026.
- On a quarterly basis, EBIT Margin rose 2710.0% year-over-year to 431.51% in Q1 2026; TTM through Mar 2026 was 382.57%, a N/A change from a year earlier, with the FY2025 full-year figure at 449.94%, down 9140.0% from the prior year.
- EBIT Margin for Q1 2026 stood at 431.51%, up from 464.82% in the prior quarter.
- Over the last five years, EBIT Margin for KURA reached as high as 268.54% in Q2 2025 and fell as low as 464.82% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Kura Oncology | 925.97 Mn | 925.97 Mn | 18.00 Mn | -431.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -431.51% |
| Dec 31, 2025 | -464.82% |
| Sep 30, 2025 | -354.78% |
| Jun 30, 2025 | -268.54% |
| Mar 31, 2025 | -458.61% |